34
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Treatment Policy rather than Patient Characteristics Determines Convection Volume in Online Post-Dilution Hemodiafiltration

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background/Aims: Sub-analyses of three large trials showed that hemodiafiltration (HDF) patients who achieved the highest convection volumes had the lowest mortality risk. The aims of this study were (1) to identify determinants of convection volume and (2) to assess whether differences exist between patients achieving high and low volumes. Methods: HDF patients from the CONvective TRAnsport STudy (CONTRAST) with a complete dataset at 6 months (314 out of a total of 358) were included in this post hoc analysis. Determinants of convection volume were identified by regression analysis. Results: Treatment time, blood flow rate, dialysis vintage, serum albumin and hematocrit were independently related. Neither vascular access nor dialyzer characteristics showed any relation with convection volume. Except for some variation in body size, patient characteristics did not differ across tertiles of convection volume. Conclusion: Treatment time and blood flow rate are major determinants of convection volume. Hence, its magnitude depends on center policy rather than individualized patient prescription.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: not found
          • Article: not found

          Excerpts from the US Renal Data System 2009 Annual Data Report.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Beta2-microglobulin.

              Among the uremic toxins in the "middle molecule" range, beta2-microglobulin (beta2-M) is certainly one of the most frequently studied compounds. Its serum level increases with the progression of chronic kidney disease, to reach very high concentrations in patients with end-stage kidney disease. It is the major protein component of dialysis-related amyloidosis, a dramatic complication which results from high extracellular concentration and posttranslational modification of beta2-M and a number of other promoters of amyloid fibril formation and deposition in osteo-articular tissues. Effective removal of beta2-M can be achieved with highly effective hemodialysis and hemodiafiltration techniques but predialysis session serum levels cannot be normalized. The prevalence and severity of beta2-M amyloidosis appear to have decreased in the last 20 years, although its occurrence may simply be delayed.
                Bookmark

                Author and article information

                Journal
                BPU
                Blood Purif
                10.1159/issn.0253-5068
                Blood Purification
                S. Karger AG
                0253-5068
                1421-9735
                2014
                July 2014
                12 June 2014
                : 37
                : 3
                : 229-237
                Affiliations
                aDepartment of Nephrology, VU Medical Center, Amsterdam, bDepartment of Nephrology, and cJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, and dDepartment of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands; eDepartment of Nephrology, Centre Hospitalier de l'Université de Montréal, St. Luc Hospital, Montréal, Canada; fInstitute for Cardiovascular Research VU Medical Center (ICaR-VU), VU Medical Center, Amsterdam, The Netherlands
                Author notes
                *Muriel Grooteman, Department of Nephrology, Vrije Universiteit Medical Center, De Boelelaan 1117, NL-1081 HZ Amsterdam (The Netherlands), E-Mail mpc.grooteman@vumc.nl
                Article
                362108 Blood Purif 2014;37:229-237
                10.1159/000362108
                24943743
                8841be1b-47ad-4b35-aecf-940efd158aac
                © 2014 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 25 October 2013
                : 06 March 2014
                Page count
                Figures: 2, Tables: 4, Pages: 9
                Categories
                Original Paper

                Cardiovascular Medicine,Nephrology
                Dialysis,Hemodiafiltration,Convection volume,Vascular access,Filtration fraction,Dialyzer

                Comments

                Comment on this article